Evidence map›Paper›PMID 32873147›Full record

Observational studyScottish medical journal2020

Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study.

Khurram Shahzad Khan, Hamish Reed-Embleton, Jen Lewis, Pamela Bain, Sajid Mahmud

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scottish medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 5 pooled it
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Khurram Shahzad KhanST6 in General Surgery, Department of Surgery, University Hospital Hairmyres, UK.ORCID https://orcid.org/0000-0002-8304-5970
Hamish Reed-EmbletonFY1 in General Medicine, Department of Medicine, University Hospital Hairmyres, UK.ORCID https://orcid.org/0000-0001-8291-0777
Jen LewisResearch Associate / Medical Statistician, Medical Statistics/Design, Trials & Statistics, School of Health and Related Research, University of Sheffield, UK.
Pamela BainST6 in General Surgery, Department of Surgery, University Hospital Hairmyres, UK.
Sajid MahmudST6 in General Surgery, Department of Surgery, University Hospital Hairmyres, UK.
Hairmyres Hospital · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHypertension is associated with an increased risk of severe outcomes with COVID-19 disease. Angiotensin Converting Enzyme (ACE) inhibitors are widely used as a first line medication for the treatment of hypertension in the UK, although their use was suggested in early reports to increase the risk associated with SARS-CoV-2 infection.

methodsA prospective cohort study of hospitalised patients with laboratory confirmed COVID-19 was conducted across three hospital sites with patients identified on the 9th April 2020. Demographic and other baseline data were extracted from electronic case records, and patients grouped depending on ACE inhibitor usage or not. The 60-day all-cause mortality and need for intubation compared.

resultsOf the 173 patients identified, 88 (50.8%) had hypertension. Of these 27 (30.7%) used ACE inhibitors. We did not find significant differences in 60-day all-cause mortality, the requirement for invasive ventilation or length of stay between our patient cohorts after adjusting for covariates.

conclusionThis study contributes to the growing evidence supporting the continued use of ACE inhibitors in COVID-19 disease, although adequately powered randomised controlled trials will be needed to confirm effects.

Indexed as

BetacoronavirusAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCoronavirus InfectionsCOVID-19FemaleHumansHypertensionMaleMiddle AgedPandemicsPneumonia, ViralProspective StudiesSARS-CoV-2ScotlandAngiotensin-Converting Enzyme Inhibitorsangiotensin converting enzyme (ACE) inhibitorHypertensionmortalitySARS-CoV-2Scotland

Identifiers

PMID32873147
PMCPMC7468667
OpenAlexW3082146827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.